ZA200803704B - Biphenyl derivatives as modulators of voltage gated ion channels - Google Patents
Biphenyl derivatives as modulators of voltage gated ion channelsInfo
- Publication number
- ZA200803704B ZA200803704B ZA2008/03704A ZA200803704A ZA200803704B ZA 200803704 B ZA200803704 B ZA 200803704B ZA 2008/03704 A ZA2008/03704 A ZA 2008/03704A ZA 200803704 A ZA200803704 A ZA 200803704A ZA 200803704 B ZA200803704 B ZA 200803704B
- Authority
- ZA
- South Africa
- Prior art keywords
- modulators
- biphenyl derivatives
- ion channels
- gated ion
- voltage gated
- Prior art date
Links
- 102000004310 Ion Channels Human genes 0.000 title abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Amplifiers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72568605P | 2005-10-12 | 2005-10-12 | |
| PCT/US2006/040156 WO2007047474A2 (en) | 2005-10-12 | 2006-10-12 | Biphenyl derivatives as modulators of voltage gated ion channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200803704B true ZA200803704B (en) | 2009-09-30 |
Family
ID=37836784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2008/03704A ZA200803704B (en) | 2005-10-12 | 2008-04-29 | Biphenyl derivatives as modulators of voltage gated ion channels |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7683083B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1934191B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009511599A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080059292A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101365690A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE551333T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006304283B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2624831A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2383090T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL190632A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20082165L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ567570A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2008118350A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007047474A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200803704B (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| EP1891063B1 (en) * | 2005-05-10 | 2012-07-25 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| KR20080021030A (ko) * | 2005-05-16 | 2008-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| CA2622076A1 (en) * | 2005-09-09 | 2007-03-15 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| WO2007047474A2 (en) * | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| JP2009512717A (ja) * | 2005-10-21 | 2009-03-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルを調節するための誘導体 |
| TW200740803A (en) * | 2005-12-21 | 2007-11-01 | Vertex Pharma | Heterocyclic derivatives as modulators of ion channels |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| JP2011503112A (ja) * | 2007-11-13 | 2011-01-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物 |
| MX2010005307A (es) * | 2007-11-13 | 2010-07-28 | Vertex Pharma | Derivados heterociclicos como moduladores de canales de iones. |
| US20110031892A1 (en) * | 2008-04-30 | 2011-02-10 | Sharp Kabushiki Kaisha | Lighting device and display device |
| WO2010002956A2 (en) * | 2008-07-01 | 2010-01-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| AR094667A1 (es) | 2013-01-31 | 2015-08-19 | Vertex Pharma | Piridonamidas como moduladores de canales de sodio |
| WO2019077106A1 (en) * | 2017-10-19 | 2019-04-25 | Esteve Pharmaceuticals, S.A. | NOVEL ALKOXYAMINO COMPOUNDS FOR TREATING PAIN AND PAIN DISEASES ASSOCIATED WITH PAIN |
| CA3105657A1 (en) | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
| CN112689629B (zh) | 2018-07-09 | 2024-04-23 | 利伯研究所公司 | 用于抑制Nav1.8的哒嗪化合物 |
| WO2020163236A1 (en) * | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Treating long qt syndrome |
| EP4334298A1 (en) | 2021-06-14 | 2024-03-13 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| AU2002223492A1 (en) | 2000-11-14 | 2002-05-27 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| CA2466491A1 (en) * | 2001-11-22 | 2003-05-30 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| JP2005509677A (ja) * | 2001-11-22 | 2005-04-14 | ビオヴィトルム・アクチボラゲット | １型１１−ベータ−ヒドロキシステロイドデヒヒドロゲナーゼの阻害剤 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| CA2539227A1 (en) * | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| CA2549651A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| WO2006089871A2 (en) * | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
| WO2007047474A2 (en) * | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
-
2006
- 2006-10-12 WO PCT/US2006/040156 patent/WO2007047474A2/en not_active Ceased
- 2006-10-12 NZ NZ567570A patent/NZ567570A/en not_active IP Right Cessation
- 2006-10-12 AT AT06816908T patent/ATE551333T1/de active
- 2006-10-12 AU AU2006304283A patent/AU2006304283B2/en not_active Ceased
- 2006-10-12 KR KR1020087011101A patent/KR20080059292A/ko not_active Withdrawn
- 2006-10-12 JP JP2008535728A patent/JP2009511599A/ja active Pending
- 2006-10-12 RU RU2008118350/04A patent/RU2008118350A/ru not_active Application Discontinuation
- 2006-10-12 EP EP06816908A patent/EP1934191B1/en not_active Not-in-force
- 2006-10-12 ES ES06816908T patent/ES2383090T3/es active Active
- 2006-10-12 CN CNA2006800448581A patent/CN101365690A/zh active Pending
- 2006-10-12 CA CA002624831A patent/CA2624831A1/en not_active Abandoned
- 2006-10-12 US US11/546,669 patent/US7683083B2/en active Active
-
2008
- 2008-04-06 IL IL190632A patent/IL190632A0/en unknown
- 2008-04-29 ZA ZA2008/03704A patent/ZA200803704B/en unknown
- 2008-05-13 NO NO20082165A patent/NO20082165L/no not_active Application Discontinuation
-
2010
- 2010-02-01 US US12/697,671 patent/US8236833B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101365690A (zh) | 2009-02-11 |
| ATE551333T1 (de) | 2012-04-15 |
| CA2624831A1 (en) | 2007-04-26 |
| EP1934191B1 (en) | 2012-03-28 |
| NZ567570A (en) | 2011-02-25 |
| WO2007047474A3 (en) | 2007-07-05 |
| US7683083B2 (en) | 2010-03-23 |
| ES2383090T3 (es) | 2012-06-18 |
| AU2006304283A1 (en) | 2007-04-26 |
| IL190632A0 (en) | 2008-11-03 |
| EP1934191A2 (en) | 2008-06-25 |
| US8236833B2 (en) | 2012-08-07 |
| KR20080059292A (ko) | 2008-06-26 |
| AU2006304283B2 (en) | 2012-01-19 |
| WO2007047474A2 (en) | 2007-04-26 |
| RU2008118350A (ru) | 2009-11-20 |
| JP2009511599A (ja) | 2009-03-19 |
| US20100130548A1 (en) | 2010-05-27 |
| NO20082165L (no) | 2008-07-09 |
| US20080113990A1 (en) | 2008-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200803704B (en) | Biphenyl derivatives as modulators of voltage gated ion channels | |
| AU2006287480A8 (en) | Bicyclic derivatives as modulators of voltage gated ion channels | |
| HUS2100051I1 (hu) | Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére | |
| WO2008014238A3 (en) | Dimeric iap inhibitors | |
| IL187382A0 (en) | Bicyclic derivatives as modulators of ion channels | |
| MX2010002028A (es) | Metodos y composiciones para modular celulas t. | |
| MX360301B (es) | Moleculas pequeñas que contienen boro como agentes antiinflamatorios. | |
| ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
| WO2007145704A3 (en) | Gemcitabine combination therapy | |
| WO2007098252A3 (en) | Methods and compositions for treating hyperalgesia | |
| NO20076306L (no) | Bicykliske derivater som modulatorer av ionekanaler | |
| MX2009001327A (es) | Compuestos de indol. | |
| WO2010138820A3 (en) | N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation | |
| BRPI0514893A (pt) | quinazolinas úteis como moduladores de canais de ìon | |
| NO20060518L (no) | Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler | |
| SG178999A1 (en) | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| WO2008014229A3 (en) | Dimeric iap inhibitors | |
| ATE540036T1 (de) | Heterocyclische derivate als ionenkanalmodulatoren | |
| WO2010068815A3 (en) | Compositions and methods for treating cellular proliferative disorders | |
| ZA200804043B (en) | Quinazolines useful as modulators of voltage gates ion channels | |
| UA99901C2 (en) | Indole compounds | |
| EP4116491A4 (en) | ASPHALT COMPOSITION | |
| WO2010138828A3 (en) | Potassium channel modulators | |
| WO2007033374A3 (en) | Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor | |
| EP4116489A4 (en) | ASPHALT COMPOSITION |